centogene is a worldwide leader in the field of genetic diagnostic testing for rare hereditary diseases, with a broad test portfolio covering over 2800 genes, biochemical tests, biomarker tests, clinical whole exome sequencing and whole genome sequencing. centogene’s mission is to support medical professionals with in-depth medical expertise in order to diagnose early the cause of the patients’ symptoms. analyzing samples from all over the world allows centogene to constantly expand its unique portfolio resulting in the largest systematic documentation of genetic results, centomd®. this mutation database integrates genetic and clinical information, enabling the highest quality, knowledge-based genetic testing and biomarker development. in addition to offering diagnostic services for individual patients, centogene is a pivotal partner to some of the most respected names in the industry. imprint centogene ag is a stock corporation ('aktiengesellschaft') incorporated under the
Company profile
Ticker
CNTG
Exchange
Website
CEO
Arndt Rolfs
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Centogene B.V.
SEC CIK
CNTG stock data
Latest filings (excl ownership)
6-K
CENTOGENE Receives Nasdaq Non-Compliance Notice
2 Apr 24
6-K
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
19 Mar 24
6-K
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
29 Feb 24
6-K
CENTOGENE Explores Strategic Alternatives
28 Feb 24
6-K
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
28 Feb 24
6-K
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
25 Jan 24
6-K
CENTOGENE Receives French Research Tax Credit Accreditation
24 Jan 24
6-K
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
23 Jan 24
6-K
CENTOGENE Announces Preliminary Full Year 2023 Revenue
18 Jan 24
6-K
CENTOGENE Announces Voting Results of Extraordinary General Meeting
19 Dec 23
Latest ownership filings
SC 13D/A
TVM Life Science Innovation I L.P.
11 Mar 22
SC 13D/A
DPE Deutsche Private Equity Gesellschaft mbH
22 Feb 22
SC 13G
PLATINUM INVESTMENT MANAGEMENT LTD
9 Dec 21
144
Notice of proposed sale of securities
12 Jul 21
144
Notice of proposed sale of securities
7 Jul 21
SC 13D/A
DPE Deutsche Private Equity Gesellschaft mbH
12 May 21
SC 13G/A
Rolfs Arndt
16 Feb 21
144
Notice of proposed sale of securities
27 Jan 21
SC 13D/A
DPE Deutsche Private Equity Gesellschaft mbH
5 Nov 20
SC 13D/A
TVM Life Science Innovation I L.P.
3 Nov 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
49.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 3.73 bn |
Total shares | 13.54 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
DPE Deutsche Private Equity Gesellschaft mbH | 8.24 mm | $36.43 mm |
TVM Life Science Innovation I | 2.80 mm | $12.37 mm |
Platinum Investment Management | 2.38 mm | $3.57 bn |
Acadian Asset Management | 31.50 k | $47.00 k |
BLK Blackrock | 21.58 k | $32.37 mm |
MS Morgan Stanley | 16.83 k | $25.25 mm |
SF Stifel Financial | 15.95 k | $23.93 mm |
BCS Barclays | 15.35 k | $23.00 k |
Two Sigma Investments | 11.92 k | $17.88 mm |
Geode Capital Management | 11.16 k | $16.73 mm |
News
Centogene Receives Non-Compliance Notification Letter Dated March 27, 2024, From Nasdaq
2 Apr 24
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders, Financial Terms Undisclosed
19 Mar 24
CENTOGENE Collaborates On Research Published In Science Showing Immunopathological Landscape Of Human Pre-TCRα Deficiency
29 Feb 24
Centogene Says It Is Exploring A Range Of Strategic Alternatives Focused On Sustainable Long-term Value Creation For The Benefit Of Its Stakeholders
28 Feb 24
Centogene And The Laboratory Of Human Genetics Of Infectious Diseases At Institut Imagine Announced Rare Disease Research Collaboration; Specific Targets Of The Collaboration Were Not Disclosed
25 Jan 24
Press releases
CENTOGENE Receives Nasdaq Non-Compliance Notice
2 Apr 24
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
29 Feb 24
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
28 Feb 24
CENTOGENE Explores Strategic Alternatives
28 Feb 24
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
25 Jan 24